论文部分内容阅读
Lomefloxacin(NY-198)是北陆制药公司中央研究所合成的新喹诺酮类抗菌剂。在日本,该公司与盐野义公司共同开发本品。 NY-198一方面保持了有氟哌酸以后的所谓氟喹诺酮类药物对革蓝氏阳性菌和阴性菌强的抗菌活性,同时在体内预防感染的效果优于同类药物,这是本品的最大特点。本品吸收、分布、代谢、排泄方面均得到改善,口服吸收好,在体内几乎不被代谢,大部分以原型由尿中排泄,血中半衰期为6～8小时,向各组织、体液中的分布良好。
Lomefloxacin (NY-198) is a new quinolone antibacterial agent synthesized by Hokuriku Central Research Institute. In Japan, the company and Yan Ye-yi companies jointly develop this product. NY-198 maintains the strong antibacterial activity of the so-called fluoroquinolones after taking norfloxacin against gram-positive and -negative bacteria. Meanwhile, the effect of preventing infection in the body is better than that of similar drugs, which is the largest Features. This product absorption, distribution, metabolism, excretion have been improved, good oral absorption, almost no metabolism in the body, most of the prototype excreted by the urine, the blood half-life of 6 to 8 hours, to the tissues, body fluids Well distributed.